Effect of raloxifene on lipid profile in postmenopausal women
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242495Keywords:
Raloxifene, Postmenopausal women, Lipid profileAbstract
Background: Menopause, a natural event in a woman’s life is characterized by loss of reproductive function and decline in estrogen levels. Menopause is not just the cessation of menstruation; it is an outward manifestation of ovarian failure due to depletion of ovarian follicles that leads to decreased estrogen levels which in turn leads to the morbidity associated with the menopause. Objectives were to evaluate serum lipid profile (baseline) of post-menopausal women with menopausal symptoms, to assess the effect of raloxifene on serum lipid levels.
Methods: Effects of raloxifene on serum lipid profile were studied in 75 healthy postmenopausal women in a prospective randomized observational study. Serum lipid levels at baseline, 3rd month and 6th month were analyzed using independent samples’ t test. The 95% confidence intervals for the difference in means were reported.
Results: At 3 months and 6 months, there was a change of 3.6% and 5.4% respectively, from baseline values in total cholesterol levels, there was change of 3.5% and 5.8% in triglyceride levels from baseline values. There was an increase of 1.4% and 3.5 % from baseline high-density lipoprotein (HDL) levels. There was a decrease of 4.9% and 9.2% from baseline low-density lipoprotein (LDL) levels; 2.6% and 4.4% from baseline VLDL.
Conclusions: Our study could lead to good practice of raloxifene in postmenopausal women and help to use Raloxifene with safety and may prevent risks of cardiovascular disease as well as the risk of death from other disease in menopausal women.
Metrics
References
Kumar P, Malhotra N. Jeffcoate’s Principles of Gynaecology. Chapter 53, Edition 7. Jaypee Brothers, New Delhi. 2008;862-3.
Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006; 355(22):2338-2347.
Bromberger JT, Karen AM, Laura LS, Sarah B, Nancy EA, Howard MK, et al. Depressive symptoms during the menopausal transition: the study of women’s health across the nation. J Affect Disord. 2007;103(1-3):267-72.
Wallace RB, Sherman BM, Bean JA, Treloar AE, Schlabaugh L. Probability of menopause with increasing duration of amenorrhea in middle-aged women. Am J Obstet Gynecol. 1979;135(8):1021-4.
Bachmann G. Physiologic aspect of natural and surgical menopause. J Reprod Med. 2001;46(3):307-15.
Dennerstein L, Smith AM, Morse C, Burger H, Green A, Hopper J, et al. Med J Aust. Menopausal symptoms in Australian women. Med J Aust. 1993;159(4):232-6.
Lasilla H, Johns NP, Neil CKO, Jeffrey J, Judith LB, Paula AWE. Alternative options to manage menopausal symptoms with a focus on melatonin and osteoporosis. Clin Pharmacol Biopharmaceut. 2014;3(1):115.
Yang F, Li N, Mihnea-Alexandru G, Ning W. Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. Pharmacological Res. 2021;166:105512.
Dayspring T, Qu Y, Keech C. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism. 2006;55(7):972-9.
Francucci CM, Pantaleo D, Iori N, Camilletti A, Massi F, Boscaro M, et al. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest. 2005;28(7):623-31.
Piperi C, Kalofoutis C, Lagogianni I, Troupis G, Kalofoutis A. Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Mol Cell Biochem. 2004;261(1-2):71-5.
Johnston CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials. Arch Intern Med. 2000;160(22):3444-50.
Matsumura M, Monden T, Nakatani Y, Shimizu H, Domeki N, Yanagi K, et al. Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment. Med Princ Pract. 2009;19(1):68-72.
Engin-Üstün Y, Ustün Y, Meydanli M, Kafkasli A. Effects of intranasal 17β-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial. Gynecol Endocrinol. 2006;22(12):676-9.
Downloads
Published
How to Cite
Issue
Section
